Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2023 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety...
February 23, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
February 21, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

- CLS-AX OASIS Results Show Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - SCS Microinjector® Featured in Favorable Data...
February 07, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
February 06, 2023 07:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Leadership Team Update

ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
February 02, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went...
November 22, 2022 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
November 10, 2022 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

ALPHARETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
November 09, 2022 07:15 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential...
November 09, 2022 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...